Incidence of persistent/late chronic anemia in newly diagnosed patients with chronic myeloid leukemia responsive to imatinib

Publisher： John Wiley & Sons Inc

E-ISSN： 1096-8652|90|2|105-108

ISSN： 0361-8609

Source： AMERICAN JOURNAL OF HEMATOLOGY, Vol.90, Iss.2, 2015-02, pp. : 105-108

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

How I treat newly diagnosed chronic myeloid leukemia in 2015

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 2, 2015-02 ,pp. : 156-161

John Wiley & Sons Inc

Access to resources Recommend Favorite

Early cytotoxic lymphocyte expansion contributes to a deep molecular response to dasatinib in patients with newly diagnosed chronic myeloid leukemia in the chronic phase: results of the D‐first study

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 9, 2015-09 ,pp. : 819-824

John Wiley & Sons Inc

Access to resources Recommend Favorite

Tolerability and efficacy of pegylated interferon‐α‐2a in combination with imatinib for patients with chronic‐phase chronic myeloid leukemia

By  

CANCER, Vol. 119, Iss. 24, 2013-12 ,pp. : 4284-4289

John Wiley & Sons Inc

Access to resources Recommend Favorite

Changes in Expression of Apoptosis-Related Genes Are Linked to the Molecular Response to Imatinib Treatment in Chronic-Phase Chronic Myeloid Leukemia Patients

By  

Acta Haematologica, Vol. 117, Iss. 2, 2006-11 ,pp. : 83-90

Karger

Access to resources Recommend Favorite

Comparative efficacy of nilotinib and dasatinib in newly diagnosed chronic myeloid leukemia: a matching-adjusted indirect comparison of randomized trials

By Signorovitch James E.   Wu Eric Q.   Betts Keith A.   Parikh Kejal   Kantor Evan   Guo Amy   Bollu Vamsi K.   Williams Denise   Wei L.J.   DeAngelo Daniel J.  

Current Medical Research and Opinion, Vol. 27, Iss. 6, 2011-06 ,pp. : 1263-1271

Informa Healthcare

Access to resources Recommend Favorite